

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : James W. West, Cameron S. Brandt, Stephen R. Jaspers
Serial No. : 10/684,149
Filed : October 10, 2003
For : PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS
Confirmation No. : 5157

Examiner : Schwadron, R. B.
Art Unit : 1644
Docket No. : 02-17
Date : October 11, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Restriction Requirement mailed September 15, 2006, has been received and reviewed.

The Office Action sets forth a restriction requirement under 35 USC §121.

Applicants were requested to elect one of four (4) designated groups as briefly noted below:

I. Claims 1-11, drawn to a polypeptide, classified in class 530, subclass 402.

II. Claims 12 and 13, drawn to ectors and host cells, classified in class 435, subclasses 325 and 320.1.

III. Claim 14, drawn to a method of making a polypeptde, classified in class 435, subclass 69.7.

IV. Claims 15-17, drawn to a method of inhibiting B cell proliferation, classified in class 514, subclass 2.

In response to the Requirement for Restriction Election, Applicants elect Group I, claims 1-11, drawn to a polypeptide, classified in class 530, subclass 402.


The Office Action sets forth a further species restriction requirement. Applicants were requested to elect (a) one extracellular domain from the group consisting of (1) amino acid residues 30 to 110 of SEQ ID NO:4, (2) amino acid residues 1 to 110 of SEQ ID NO:4, (3) amino acid residues 30 to 154 of SEQ ID NO:4, and (4) amino acid residues 1 to 154 of SEQ ID NO:4; and (b) one trimerizing polypeptide from the group consisting of (1) the NC-1 fragment of human collagen X and (1) a trimerizing fragment of Heat Shock Binding Protein-1.

In response to the Requirement for Species Election, Applicants elect (a) the extracellular domain of (1) amino acid residues 30 to 110 of SEQ ID NO:4 and (b) the trimerizing polypeptide of the NC-1 fragment of human collagen X.

It is believed that no fee is due. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Early reconsideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6627.

Respectfully Submitted,



Jennifer K. Johnson, J.D.
Registration No. 43,696

Customer No. 10117
ZymoGenetics, Inc.